These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22123598)

  • 1. Physico-chemical aspects of lactose for inhalation.
    Kou X; Chan LW; Steckel H; Heng PW
    Adv Drug Deliv Rev; 2012 Mar; 64(3):220-32. PubMed ID: 22123598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lactose characteristics and the generation of the aerosol.
    Pilcer G; Wauthoz N; Amighi K
    Adv Drug Deliv Rev; 2012 Mar; 64(3):233-56. PubMed ID: 21616107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces.
    Zhou QT; Morton DA
    Adv Drug Deliv Rev; 2012 Mar; 64(3):275-84. PubMed ID: 21782866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dry powders for oral inhalation free of lactose carrier particles.
    Healy AM; Amaro MI; Paluch KJ; Tajber L
    Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of carrier particle shape on dry powder inhaler performance.
    Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
    Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect?
    de Boer AH; Chan HK; Price R
    Adv Drug Deliv Rev; 2012 Mar; 64(3):257-74. PubMed ID: 21565232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
    Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
    Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lactose as a carrier for inhalation products: breathing new life into an old carrier. Preface.
    Marriott C; Frijlink HW
    Adv Drug Deliv Rev; 2012 Mar; 64(3):217-9. PubMed ID: 22146699
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
    Donovan MJ; Smyth HD
    Int J Pharm; 2010 Dec; 402(1-2):1-9. PubMed ID: 20816928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers.
    Jones MD; Young P; Traini D
    Adv Drug Deliv Rev; 2012 Mar; 64(3):285-93. PubMed ID: 22265843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for reduction of cohesive forces between carrier and drug in DPI formulation.
    Desai SS; Aher AA; Kadaskar PT
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1589-98. PubMed ID: 23050727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative carriers in dry powder inhaler formulations.
    Rahimpour Y; Kouhsoltani M; Hamishehkar H
    Drug Discov Today; 2014 May; 19(5):618-26. PubMed ID: 24269834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing the Surface Roughness Length Scales of Lactose Carrier Particles in Dry Powder Inhalers.
    Tan BMJ; Chan LW; Heng PWS
    Mol Pharm; 2018 Apr; 15(4):1635-1642. PubMed ID: 29490144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation development of inhalation powders for FK888 with carrier lactose using Spinhaler and its absorption in healthy volunteers.
    Nakate T; Yoshida H; Ohike A; Tokunaga Y; Ibuki R; Kawashima Y
    J Control Release; 2004 May; 97(1):19-29. PubMed ID: 15147801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Dry Powder Inhaler Performance by Surface Roughening of Lactose Carrier Particles.
    Tan BM; Chan LW; Heng PW
    Pharm Res; 2016 Aug; 33(8):1923-35. PubMed ID: 27091033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
    Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proposed definition of the 'activity' of surface sites on lactose carriers for dry powder inhalation.
    Grasmeijer F; Frijlink HW; de Boer AH
    Eur J Pharm Sci; 2014 Jun; 56():102-4. PubMed ID: 24613490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.